Comparison of DESs in AMI Patients With MS
cacy. 4-6 Zotarolimus-eluting stents (ZES) are the newer firstgeneration DES, composed of a new antiproliferative agent and a cobalt-based alloy stent platform integrated with biocompatible phosphorylcholine polymer. 7 This was expected to be less prone to thrombosis and to have efficacy similar to that of the first-generation DES. Although ZES are increasingly used for the treatment of patients with STEMI, and although randomized comparison with sirolimus-eluting stents (SES) in the ENDEAVOR III trial showed similar clinical outcomes, there have been few direct comparisons of outcomes among the currently approved DES in these patients. 7- 10 Potential differences in safety and efficacy between DESs might be of particular importance when treating high-risk patients. In particular, patients with metabolic syndrome (MS) have been shown to have higher cardiovascular risk, 11-13 but no data are available on the direct comparison of the clinical outcomes between ZES, SES, and paclitaxel-eluting stents (PES) in these patients complicated with STEMI. The aim of the present study was to compare the clinical outcomes of ZES, SES, and PES as primary PCI in STEMI patients with MS.
Methods

Subjects
The Korea Acute Myocardial Infarction Registry (KAMIR) is a prospective, multi-center, observational registry designed to examine current epidemiology, in-hospital management, and outcome of patients with acute myocardial infarction (MI) in Korea for the commemoration of the 50 th anniversary of the Korean Circulation Society. 14, 15 The registry consists of 50 community and teaching hospitals with facilities for primary PCI and on-site cardiac surgery. Data were collected by a trained study coordinator using a standardized case report form and protocol. The ethics committee at each participating institution approved the study protocol. Among the 14,072 patients with acute MI between November 2005 and December 2007, 1,768 eligible STEMI patients with MS who underwent primary PCI were sorted according to DES type and followed up during 1 year. Patients were excluded if they had any general contraindication to the revascularization procedure and pharmacologic therapies, had undergone previous PCI or coronary artery bypass graft of the infarct-related artery, or had an estimated life expectancy <12 months. These patients were grouped based on the types of DES: a PES group (Taxus, Boston Scientific, Natick, MA, USA), a SES group (Cypher, Cordis, Miami Lakes, FL, USA), and a ZES group (Endeavor, Medtronic Vascular, Santa Rosa, CA, USA). There are no specific criteria for selecting the type of DES.
Study Design
Patients were enrolled in the registry if they were admitted to participating hospitals with a suspected diagnosis of MI. A diagnosis of MI was made in the presence of serial increases in at least one serum biochemical markers of cardiac necrosis (eg, creatine kinase-myoglobin, troponin I and T), associated with typical electrocardiographic changes and/or typical symptoms suggestive of acute MI. 16 Patients with ST-segment elevation ≥1 mm in ≥2 extremity electrocardiographic leads or ≥2 mm in ≥2 contiguous precordial leads or new left bundle branch block on the admission electrocardiogram were defined as having STEMI. Reperfusion was expected to be achieved within 6 h after onset of symptoms, and the native coronary artery was considered to be suitable for primary PCI.
All patients received ≥100 mg of aspirin and a 300-600-mg loading dose of clopidogrel and unfractionated heparin (50-70 U/kg) to maintain an activated clotting time at >250-300 s before, or during the procedure. Loading doses of aspirin and clopidogrel were given after patients agreed to undergo PCI. The maintenance dose was 100 mg/day for aspirin and 75 mg/day for clopidogrel. Data given as n (%) or mean ± SD. ACC/AHA, American College of cardiology/American Heart Association; TIMI, Thrombolysis In Myocardial Infarction.
Other abbreviations see in Table 1 . Table 1 .
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We analyzed baseline demographic and clinical characteristics and relevant laboratory results. Echocardiography was performed in all patients before discharge. The morphology of lesion in coronary angiography was classified according to the criteria of the American College of Cardiology/American Heart Association (ACC/AHA). 17 The degree of coronary flow was classified using Thrombolysis In Myocardial Infarction (TIMI) score. 18 The primary endpoint was major adverse cardiac events (MACE) at the 12-month clinical follow-up and MACE were defined as the composite of (1) all-cause death; (2) recurrent MI; and (3) target lesion revascularization (TLR). Recurrent MI was defined as the recurrence of symptoms or new electrocardiographic changes compatible with MI in association with a rise in cardiac enzymes at least twice the upper limit of normal. TLR was defined as any revascularization of the target lesion due to re-stenosis or reocclusion within 5 mm proximal or distal to the stent. Secondary endpoint included individual components of the composite primary endpoint and stent thrombosis. Stent thrombosis was defined as definite and probable stent thrombosis according to the Academic Research Consortium definition. 19 Major bleeding was defined as any intracranial bleeding, bleeding with a hemoglobin decrease of >5 g/dl, or hematocrit decrease of >15%, as judged by the TIMI investigators. All data were recorded on a standardized, electronic, web-based registry at http://www. kamir.or.kr. nition proposed by the American Heart Association/National Heart, Lung, and Blood Institute (AHA/NHLBI). Although the AHA/NHLBI guideline recommended the definition of IFG at or above 100 mg/dl, 20 the present study adopted the NCEP-ATP III guideline. All patients were reviewed immediately after admission to emergency department, and biological measurements were performed in the fasting state during the hospital stay.
Definition of MS
Statistical Analysis
All analyses were done using SPSS for Windows, version 17.0 (Chicago, IL, USA). Continuous variables are expressed as mean ± SD and analyzed using ANOVA. Categorical variables are expressed as percentages and were compared using the chi-squared test. All statistical tests were 2-tailed, with statistical significance defined as a P<0.05. Adjusted survival curves were calculated with the use of Cox regression models. In order to adjust confounding factors in Cox regression models, we included variables as covariates that had P<0.2 on univariate analysis for endpoints and other variables that have been reported to be associated with prognosis of patients with acute MI. Included variables were age, male gender, history of hypertension, history of DM, history of dyslipidemia, family history of coronary artery disease, previous MI, current smoker, Killip class on presentation, left ventricular ejection fraction, symptom to balloon time, serum creatinine level, creatine kinase-myoglobin, use of glycoprotein IIb/IIIa inhibitor, left main complex disease as culprit lesion, multivessel disease, lesion complexity, post-procedural TIMI flow, stent diameter, stent length, and discharge medications including aspirin, clopidogrel, cilostazol, β-blocker, angiotensin-converting enzyme inhibitor, angiotensin II receptor blocker and statin. The results are given as adjusted hazard ratio (HR) with 95% confidence interval (95%CI).
Results
Baseline Characteristics and Angiographic Findings
A total of 1,768 patients who presented with acute STEMI for primary PCI were included in the present study. The study group was divided into 3 groups according to DES type (PES group, 634 patients; SES group, 906 patients; ZES group, 228 patients). The baseline clinical characteristics are listed in Table 1 and there were no significant differences between the 3 groups. Dyslipidemia was defined as history of dyslipidemia or taking medication for dyslipidemia, not by laboratory findings during admission. Therefore, the prevalence of dyslipidemia was low. Also, the discharge medications are Table 1 . Between the 3 groups, no significant differences were present in the type of medications that can affect the clinical outcome such as antiplatelet agents, β-blockers, and statins. Table 2 lists the coronary angiographic and procedural characteristics. The location and complexity of the infarct-related artery and post-procedural TIMI flow grade were similar between the 3 groups. Although the ZES group had a lower incidence of 3-vessel disease and a lower tendency of glycoprotein IIb/IIIa inhibitor usage compared with other groups, there were no statistically meaningful differences. The SES group, however, had a longer stent length, and the PES group had more stents implanted than the other groups.
In-Hospital Outcomes and MACE
The in-hospital mortality rate, incidence of acute stent thrombosis, and incidence of major bleeding events were similar between the 3 groups ( Table 3 ). The rate of follow-up coronary angiography was 41.5% (263/634) in the PES group, 48.9% (443/906) in the SES group, and 40.1% (91/228) in the ZES group (P=0.511). This relatively high rate of followup angiography might be caused by enrollment of high-risk patients, that is, the STEMI patients with MS. Principally, the investigators recommended follow-up angiography for all enrolled patients. Stent thrombosis during admission occurred in 2 patients in the PES group, in 4 patients in the SES group, and in 1 patient in the ZES group (P=0.773). The cumulative incidence of primary endpoints at the 12 months clinical follow-up examination was not significantly different between the 3 groups (P=0.086). Adjusted survival curves did not show meaningful differences in incidence of primary endpoint (Figure 1) , TLR (Figure 2) , and death or recurrent MI (Figure 3) . Cumulative stent thrombosis during the follow-up period occurred less often in the PES group, but the difference was not statistically different among the 3 groups (P=0.448).
Discussion
In the present study we compared mid-term clinical outcomes after implantation of PES, SES, or ZES for the treatment of STEMI in patients with MS in the large dedicated registry data to date. The major findings of the present study are as follows: (1) there was no difference in the overall rate of MACE at 12 months among the PES, SES, and ZES groups; and (2) the rate of TLR was not meaningfully different among the 3 DES. MS is rapidly increasing in frequency. Also, MS is known to be associated with increased risk of death and cardiovascular events in patients with MI. 21 Considering that MS is frequent in real-world practice, it may be very important to investigate which DES is most effective in treating MS patients. There are very limited data, however, regarding comparisons among DESs in the treatment of STEMI patients with MS. Therefore, we compared the mid-term clinical outcomes after PCI with the 3 most widely available DES: PES, SES, and ZES, using the KAMIR data.
Stent implantation has improved procedural success and long-term outcomes, and reduced clinical and angiographic re-stenosis compared with plain old balloon angioplasty, so it has become the preferred approach for treating STEMI. 2, 22 As compared with BMS, DES decrease angiographic restenosis and the necessity of repeated revascularization by reducing neointimal hyperplasia, so many interventionists are currently using DES for patients with STEMI. Concerns remain, however, over the use of DES in this situation because patients with STEMI are expected to be at higher risk of stent thrombosis. The Global Registry of Acute Coronary Events (GRACE) registry data showed that patients with STEMI who had DES implanted were at higher risk of dying compared to patients who had BMS. 23 First-generation DES are known to be effective in lowering the risk of re-stenosis compared to BMS. In the setting of STEMI, there were no differences in MACE rates between PES and SES, although angiographic re-stenosis rate at 6 months was lower for SES implantation. A pre-clinical study showed that the ZES, a newer first-generation DES based on a different type of biostable polymer, induced less inflammation compared with past first-generation DES and improved arterial healing. 30 In the ENDEAVOR III study, increased neointimal hyperplasia and greater angiographic late lumen loss using ZES compared to SES were observed, but the clinical outcomes were not different between the 2 DES groups. 9 In the present study there were no significant differences in repeat revascularization rate and 1-year mortality among the 3 DES in MS patients within the setting of STEMI. The SORT OUT III study, however, showed that SES is superior to ZES for low-risk patients receiving routine clinical care during an 18-month follow-up. 31 The discrepancy of the outcomes between the present study and SORT OUT III study might be due to enrolled patient characteristics and the clinical setting. Stent thrombosis is a dramatic clinical event associated with MI and frequent mortality. Although the ZES group was expected to have a lower rate of stent thrombosis compared to earlier first-generation DES, stent thrombosis occurred at a similar rate in the present study and in a randomized trial. 32 Also, another randomized trial in Korea (the ZEST trial: "Comparison of the Efficacy and Safety of Zotarolimus-Eluting Stent versus Sirolimus-Eluting stent and Paclitaxel-Eluting Stent for Coronary Lesions") showed that ZES is significantly less favorable than SES in the rate of stent thrombosis (0% in SES, 0.7% in ZES, 0.8% in PES). In the ZEST trial, patients with STEMI and severe left ventricular dysfunction were excluded, and these factors are known to be independent predictors of stent thrombosis. 33 Therefore the difference in enrolled patient characteristics might be a reason for this disparity.
Even though these 3 DES rely on different mechanisms of action, the clinical outcomes at 12 months in the present large comparison indicate that, in real-world practice, the selection of either PES, SES, or ZES results in almost identical clinical results. All these findings suggest that these 3 DES may be equally safe and effective for MS patients in the setting of STEMI. Hence, the presence of MS may not affect the selection of DES for STEMI patients in the era of primary PCI.
Study Limitations
The present study had the inherent limitations of any nonrandomized multicenter registry. First, the registry findings can be limited by low rates of enrollment and underreporting of events, so they could have resulted in a selection bias, although they reflect the real world better than controlled randomized studies. Other selection bias might develop because selection of the type of DES was mainly performed at the operator's discretion. Also, it is possible that some potential confounders were included in the analysis. The KAMIR database, however, was relatively large and closely monitored, and included patients treated at hospitals of various sizes and settings, making it more representative of current practice patterns than a single-site database. Second, the number of patients who had undergone PES, SES, and ZES implantation was unequal. Thus, the data might lack precision for uncommon clinical events, including stent thrombosis. In the present trial, however, revascularization and MACE rates were clinically driven and thus were as close to reality as possible. Third, the present registry data did not include adiponectin plasma levels. It is generally considered that adiponectin plasma level is an important factor for MACE in patients with STEMI, and the relationship between waist circumference and adiponectin level was unclear. Therefore the lack of adiponectin plasma level could be a limitation. Finally, 12-month follow-up may be too short for conclusive determination of the long-term safety of DES in the setting of STEMI. A larger and more adequately powered prospective randomized study of a longer duration may be needed to clarify this issue.
Conclusions
Drug-eluting stent may be safe and effective in primary PCI for STEMI patients with MS, with no significant differences in MACE and stent thrombosis among the 3 DES.
